Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | F2R | P25116 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193765 | 0.89 | MAPK1 (0.53) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL8796753 | 0.85 | CYP4F2 (0.60) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL8867339 | 0.85 | MAPK1 (0.58) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL5106598 | 0.82 | MEN1 (0.65) | MAPTMAPK1HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6214761 | 0.82 | MAPK1 (0.65) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL6212581 | 0.82 | MAPK1 (0.61) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL8867305 | 0.82 | MAPT (0.61) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL12569392 | 0.81 | MAPK1 (0.59) | MAPTMAPK1LMNAHSD17B10ALDH1A1 | |
| SCHEMBL5353446 | 0.81 | MEN1 (0.63) | MAPTMAPK1HSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6211383 | 0.81 | MAPT (0.56) | MAPTMAPK1LMNAHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288273-A1 | Antibacterial agents | BOYER FREDERICK E JR | 2005-12-29 | — | — | US | disclosed |
| EP-1594494-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1594865-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040224939-A1 | Antibacterial agents | CHUPAK LOUIS S (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004069832-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069244-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224939-A1 | Antibacterial agents | MRPL21, RPN2, FBL | MAPT 4424/4885MAPK1 2722/4885LMNA 2919/4885 |
| US-20050288273-A1 | Antibacterial agents | MRPL21, RPN2, FBL | MAPT 4424/4885MAPK1 2722/4885LMNA 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.